Evaluating Pharmacokinetics of Intranasal Ketorolac, Pain
Conditions
Keywords
Intranasal, Ketorolac, Pharmacokinetics, Pediatric
Brief summary
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is typically given to both adults and children by the intravenous (IV) or intramuscular (IM) route for analgesic purposes. Ketorolac can also be given by the intranasal (IN) route using a mucosal atomization device (MAD). We aim to study the pharmacokinetics of ketorolac when administered by the IN route using the MAD.
Detailed description
The intranasal (IN) route of administering medications is an effective means of delivering analgesics to children in a painless and minimally distressing manner, especially in comparison to traditional means of intravenous (IV) or intramuscular (IM) administration, which require a painful and distressing needle stick. Ketorolac is an analgesic that is commonly administered to children, and can be given by the IN route, in addition to the IV and IM routes. However, the pharmacokinetics of intranasal ketorolac when administered in children has only been described in a limited fashion. The administration of IN ketorolac in children, using the proprietary SPRIX device, which atomizes a fixed amount of ketorolac, produces serum concentrations of ketorolac that are associated with analgesia. However, the concentrations of ketorolac achieved using a mucosal atomization device (MAD) has not yet been evaluated in children presenting to the emergency department. The MAD is a plastic device that attaches to the top of a syringe (see figure). The MAD is much more commonly used for atomizing medications; allows a variable dosage to be administered; and has been shown to be a means of effectively delivering other analgesics and sedatives intranasally. The purpose of this study is to assess the pharmacokinetics of IN ketorolac when using a MAD to deliver the medication in children presenting to the emergency department. We will determine the maximum serum concentration achieved (Cmax), time to maximum serum concentration achieved (Tmax), and bioavailability (compared to IV ketorolac) when ketorolac is administered intranasally using a MAD.
Interventions
DRUGKetorolac
Non-steroidal anti-inflammatory drug
Sponsors
Columbia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Present to the emergency department with a painful condition for which the treating physician decides to administer ketorolac as part of their usual care.
Exclusion criteria
* Known allergy to ketorolac * Contraindication to receiving ketorolac * Receiving any NSAID within the past 6 hours * Presence of an intranasal obstruction that cannot be readily cleared using suction or nose-blowing * Inability to speak English or Spanish * Critical illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of intranasal ketorolac | 60 minutes | Maximum serum concentration of ketorolac, after intranasal administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax of intranasal ketorolac | 6 hours | Time to maximum serum concentration of ketorolac, after intranasal administration |
| Bioavailability of intranasal ketorolac | 6 hours | Bioavailability of intranasal ketorolac; expressed as a percentage (numerator = serum levels achieved by intranasal administration, denominator = serum levels achieved by intravenous administration) |
Countries
United States
Outcome results
None listed